Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation (2019 - 2025)

Historic Accumulated Depreciation for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $20.1 million.

  • 4D Molecular Therapeutics' Accumulated Depreciation rose 2952.23% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 2952.23%. This contributed to the annual value of $16.6 million for FY2024, which is 3899.6% up from last year.
  • 4D Molecular Therapeutics' Accumulated Depreciation amounted to $20.1 million in Q3 2025, which was up 2952.23% from $18.8 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Accumulated Depreciation peaked at $20.1 million during Q3 2025, and registered a low of $4.2 million during Q1 2021.
  • Its 5-year average for Accumulated Depreciation is $10.7 million, with a median of $9.8 million in 2023.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Accumulated Depreciation soared by 6131.96% in 2023, and later soared by 2952.23% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Accumulated Depreciation stood at $5.3 million in 2021, then surged by 45.13% to $7.7 million in 2022, then soared by 54.4% to $11.9 million in 2023, then surged by 39.0% to $16.6 million in 2024, then rose by 20.97% to $20.1 million in 2025.
  • Its Accumulated Depreciation stands at $20.1 million for Q3 2025, versus $18.8 million for Q2 2025 and $17.6 million for Q1 2025.